Top Biotechnology Acquirers (2006-2026)

Tracked deals

675

675 tracked deals across 2006-2026.

Buyer mix

Strategic-led

587 strategic · 205 pe

Top trend

Volume peaked in 2022

114 tracked deals announced in 2022.

Primary Insight

What Stands Out

  • Revvity is expanding drug discovery and preclinical research tooling via the planned acquisition of Human Cell Design (France).
  • Pipeline-focused consolidations appear in deals like Tarsus Pharmaceuticals acquiring Alkeus Pharmaceuticals (retina; gildeuretinol/ALK-001 for Stargardt).
  • Platform and capability-building themes show up in Holiferm + Organica UK, combining biosurfactant technology with formulation and finished-product capabilities.
  • Large-capital strategic options and structured payments are reflected in Johnson & Johnson’s exclusive option to acquire Sail Biomedicines.
  • Deal activity includes cross-border combinations, with notable recent locations in the United States, UK, France, Germany, and Iceland.

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Find buyers like these for your deal

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Biotechnology deal →
Buyer # Deals Focus Type
Ampersand Capital Partners 23 Middle-market private equity firm focused on growth-orien... PE
Eli Lilly and Company 22 Global pharmaceutical company that discovers, develops an... Strategic
AbbVie 7 Global biopharmaceutical company focused on discovery, de... Strategic
ARCHIMED 6 Healthcare-focused private equity firm investing in Europ... PE
Charles River Laboratories International, Inc. 6 Global provider of preclinical and clinical support, labo... Strategic
Novartis 6 Global pharmaceutical company developing and commercializ... Strategic
AstraZeneca 5 Global, science-led biopharmaceutical company focused on ... Strategic
Calibre Scientific 5 Diversified global provider of life‑science reagents, too... Strategic
GHO Capital Partners LLP 5 London-based specialist private equity investor focused o... PE
Gilead Sciences, Inc. 5 Research-based biopharmaceutical company that discovers, ... Strategic

Acquisition Volume in Biotechnology by Year

Last 10 years

Acquisition volume by year Annual acquisition counts for the last 10 years for Top Biotechnology Acquirers (2006-2026). 4 2017 2 2018 29 2019 62 2020 97 2021 114 2022 91 2023 90 2024 83 2025 ~113 est. 90 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Fresenius Acquires Remaining 45% of mAbxience for Up to €750 Million
    September 30, 2026
    Buyer
    Fresenius SE & Co. KGaA
    Target
    mAbxience
    Seller
    Insud Pharma, Invim Corporativo
    Industry
    Biotechnology
    Location
    Spain
    Type
    Buyout

    Fresenius SE & Co. KGaA acquired the remaining 45% stake in mAbxience from Insud Pharma and Invim Corporativo for total cash consideration of up to €750 million, giving Fresenius full ownership. The transaction completes Fresenius’ 2022 entry, creating a vertically integrated biosimilars platform spanning development, manufacturing, regulatory, and commercialization.

  • AVS Bio (Arlington Capital Partners platform) Acquires Biorbyt Ltd.
    September 23, 2026
    Buyer
    AVS Bio, Arlington Capital Partners
    Target
    Biorbyt Ltd.
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    AVS Bio, a portfolio company of Arlington Capital Partners, announced it has acquired Biorbyt Ltd., a global supplier of bio-reagents and related biomaterials for life science research. The acquisition is intended to expand AVS Bio’s biomaterials catalog and add Biorbyt’s advanced ecommerce platform to improve global distribution capabilities.

  • Tessenderlo Group Completes Minority Equity Investment in FMC Corporation
    September 23, 2026
    Buyer
    Tessenderlo Group, FMC Corporation
    Target
    FMC Corporation
    Industry
    Biotechnology
    Location
    United States
    Type
    Growth capital

    FMC Corporation and Tessenderlo Group announced the closing of Tessenderlo Group’s minority equity investment in FMC. Tessenderlo purchased 30,319,166 shares of FMC common stock for approximately $403 million, representing about 20% ownership.

  • Aethlon Medical to Merge with North Immunology in All-Stock Deal and $180 Million Private Placement
    September 18, 2026
    Buyer
    North Immunology
    Target
    Aethlon Medical, North Immunology
    Industry
    Biotechnology
    Type
    Buyout

    Aethlon Medical has entered into a definitive agreement to merge with privately held biotechnology company North Immunology in an all-stock transaction. The deal also includes an oversubscribed $180 million private placement to fund North Immunology’s lead atopic dermatitis program, NOR-101, through multiple clinical readouts.

  • Holiferm and Organica UK Combine to Build Integrated Biotech and Sustainable Products Platform
    September 12, 2026
    Buyer
    Holiferm, Organica UK
    Target
    Holiferm, Organica UK
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    Holiferm and Organica UK announced a strategic combination that brings together Holiferm’s biosurfactant technology and manufacturing with Organica’s formulation and finished-product capabilities. The combined platform will span ingredient development through product manufacturing and commercialization, supported by a continuing commercial partnership with Sadorp.

  • Revvity to Acquire Human Cell Design to Expand Metabolic and GLP-1 Drug Discovery Tools
    September 11, 2026
    Buyer
    Revvity, Inc.
    Target
    Human Cell Design
    Industry
    Biotechnology
    Location
    France
    Type
    Buyout

    Revvity entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human pancreatic beta cell models and preclinical research solutions for diabetes, obesity, and other metabolic diseases. The acquisition is expected to strengthen Revvity’s life sciences tools for drug discovery, screening, and preclinical research, including next-generation GLP-1 and other metabolic therapies.

  • Daesang Acquires AMINO GmbH
    September 9, 2026
    Buyer
    Daesang
    Target
    AMINO GmbH
    Industry
    Biotechnology
    Location
    Lower Saxony, Germany
    Type
    Buyout

    Daesang, a Korean food and biotechnology company, acquired Germany-based AMINO GmbH to expand into the biopharmaceutical sector. The acquisition adds pharmaceutical-grade amino acid purification technology, European regulatory expertise, and a global customer network, supporting Daesang’s push from general-purpose amino acids into high-purity materials for medical infusion solutions, clinical nutrition, and biopharmaceuticals.

  • VION Biosciences Acquires Prolytix
    September 8, 2026
    Buyer
    VION Biosciences, Edgewater Capital Partners
    Target
    Prolytix
    Seller
    Edgewater Capital Partners
    Industry
    Biotechnology
    Location
    Ohio, United States
    Type
    Buyout

    VION Biosciences announced the closing of its acquisition of Prolytix, a provider of regulated bioanalytical and CMC services, research reagents, and custom sample collection products. The deal is intended to strengthen VION’s integrated platform across biopharma services and diagnostic workflow inputs, including regulated large-molecule testing and workflow-critical reagents and IVD materials.

  • Eli Lilly to Acquire Merida Biosciences
    August 31, 2026
    Buyer
    Eli Lilly and Company
    Target
    Merida Biosciences
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Eli Lilly and Company has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The acquisition is intended to expand Lilly’s precision immunology platform for selectively targeting disease-causing antibodies across autoimmune and allergic conditions, including Graves’ disease and thyroid eye disease.

  • CDT Equity Inc. SAFE Investment in Pep'd Inc.
    August 25, 2026
    Buyer
    CDT Equity Inc.
    Target
    Pep'd Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Growth capital

    CDT Equity Inc. entered into a SAFE note with Pep'd Inc. to expand its exposure to the growing US peptide market. The SAFE is expected to convert into Safe Preferred Stock upon Pep'd closing an equity financing, using a $10,000,000 valuation cap.

  • Global UAV Technologies to acquire Nexus Peptide Sciences via three-cornered amalgamation
    August 24, 2026
    Buyer
    Global UAV Technologies Ltd., 1604759 B.C. Ltd.
    Target
    Nexus Peptide Sciences Inc.
    Seller
    Securityholders of Nexus Peptide Sciences Inc.
    Industry
    Biotechnology
    Location
    British Columbia, Canada
    Type
    Buyout

    Global UAV Technologies Ltd. entered into a definitive amalgamation agreement to complete a three-cornered amalgamation with Nexus Peptide Sciences Inc. to acquire all outstanding Nexus shares. Nexus shareholders will receive shares and warrants of the resulting issuer, and Global UAV plans to use proceeds primarily to develop and assess Nexus’s peptide formulations and IP.

  • Fulcrum Therapeutics and Slate Medicines Announce Definitive All-Stock Merger With $245M Private Placement
    August 21, 2026
    Buyer
    Slate Medicines (resulting combined company)
    Target
    Fulcrum Therapeutics, Slate Medicines
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Fulcrum Therapeutics and Slate Medicines entered into a definitive all-stock merger agreement to combine into a Nasdaq-listed biotechnology company operating as Slate Medicines under ticker SLTE. The transaction is supported by an oversubscribed concurrent $245 million private placement led by Frazier Life Sciences, with committed participation from multiple healthcare investors and expected to fund operations into 2029.

  • BioMarin Pharmaceutical Acquires Alesta Therapeutics (ALE1)
    August 18, 2026
    Buyer
    BioMarin Pharmaceutical Inc.
    Target
    Alesta Therapeutics
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    BioMarin Pharmaceutical entered into a definitive agreement to acquire Alesta Therapeutics to gain its lead clinical-stage asset, ALE1, an orally active small molecule for hypophosphatasia (HPP). BioMarin completed the acquisition in early September 2026, and Alesta Therapeutics became a wholly owned subsidiary, with the deal focused on ALE1 after Alesta spun out non-ALE1 assets prior to closing.

  • Valerio Therapeutics Acquires Etherna Immunotherapies
    August 17, 2026
    Buyer
    Valerio Therapeutics
    Target
    Etherna Immunotherapies NV
    Industry
    Biotechnology
    Location
    Antwerp, Belgium
    Type
    Buyout

    Valerio Therapeutics acquired 100% of Etherna Immunotherapies at an enterprise value of €30 million, funded through cash consideration and contributions of Etherna shares. The acquisition combines Valerio’s cell-targeting technology with Etherna’s RNA chemistry, lipid nanoparticle delivery and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.

  • Ensysce Biosciences Acquires Cy Biopharma
    August 6, 2026
    Buyer
    Ensysce Biosciences, Inc.
    Target
    Cy Biopharma, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Ensysce Biosciences completed its acquisition of Cy Biopharma in a stock-for-stock merger. Concurrently, Ensysce entered into a definitive private placement financing expected to raise about $21.5 million at initial close, plus an additional up to $38.6 million upon a clinical milestone, to fund development of Cy Biopharma’s lead program CY200 for complex regional pain syndrome.

  • Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals in $800M Deal
    August 6, 2026
    Buyer
    Tarsus Pharmaceuticals, Inc.
    Target
    Alkeus Pharmaceuticals, Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Tarsus Pharmaceuticals entered into a definitive agreement to acquire privately held retinal-disease biotechnology company Alkeus Pharmaceuticals. The deal values Alkeus at $450 million upfront (including $270 million cash and $180 million in Tarsus stock) plus up to $350 million in milestone payments tied to U.S. regulatory approval and first commercial sales. Closing is expected later in 2026, subject to customary conditions and the Hart-Scott-Rodino waiting period.

  • Johnson & Johnson Options to Acquire Sail Biomedicines for $2.58 Billion
    August 2, 2026
    Buyer
    Johnson & Johnson
    Target
    Sail Biomedicines
    Industry
    Biotechnology
    Location
    United States
    Type
    Growth capital

    Johnson & Johnson entered into strategic agreements with Sail Biomedicines to collaborate on in vivo CAR-T therapies and secured an exclusive option to acquire Sail for $2.58 billion. The deal includes initial payments totaling $785 million (including a $465 million equity investment) and up to $140 million in additional development milestone payments, with the $2.58 billion payable if the option is exercised.

  • Processa Pharmaceuticals Acquires Vidya Therapeutics and Raises ~$200M for VT-7208 Phase 2 Programs
    July 31, 2026
    Buyer
    Processa Pharmaceuticals, Inc.
    Target
    Vidya Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    Florida, United States
    Type
    Buyout

    Processa Pharmaceuticals acquired Vidya Therapeutics in a stock-for-stock transaction to bring Vidya’s CNS-penetrant, once-daily BTK inhibitor VT-7208 into Processa’s pipeline. Concurrently, Processa entered into a definitive agreement for an approximately $200 million private placement, with proceeds intended to fund VT-7208’s parallel Phase 2 proof-of-concept studies across food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).

  • Yarrow Bioscience Completes Merger with VYNE Therapeutics
    July 27, 2026
    Buyer
    Yarrow Bioscience, Inc.
    Target
    VYNE Therapeutics Inc.
    Industry
    Biotechnology
    Type
    Buyout

    Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics, with the combined company operating as Yarrow Bioscience, Inc. The transaction follows previously announced private financings totaling approximately $200 million and includes the initiation of dosing in a Phase 2a/2b trial of YB-101 for Graves' disease and thyroid eye disease.

  • Scancell Holdings Merges With Neuphoria Therapeutics Under $89 Million Financing Plan
    July 24, 2026
    Buyer
    Scancell Holdings
    Target
    Neuphoria Therapeutics
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    Scancell Holdings and Neuphoria Therapeutics have entered an all-share merger agreement in which Scancell will acquire Neuphoria. The combined company is expected to operate under the Scancell name and list on Nasdaq, alongside Scancell’s existing AIM listing, and finance the transaction with up to $89 million in equity and debt.

  • Synaptiq Therapeutics launches after acquisition of Nobias Therapeutics' NB-001 (now SYN-001)
    July 23, 2026
    Buyer
    Synaptiq Therapeutics, Sanos Group, Arctic Therapeutics, AxUM Securities, Nobias Therapeutics (equity retained)
    Target
    Nobias Therapeutics, NB-001 program (now SYN-001)
    Seller
    Nobias Therapeutics
    Industry
    Biotechnology
    Location
    Iceland
    Type
    Buyout

    Synaptiq Therapeutics, a newly launched privately held clinical-stage biotechnology company, was formed through the acquisition of Nobias Therapeutics’ lead clinical program NB-001, which is now called SYN-001. The entity brings together European and US investors and operational capabilities from partners including Arctic Therapeutics (development platform and clinical operations) and Sanos Group (clinical development and CRO capabilities) to advance SYN-001 through late-stage development for neuropsychiatric symptoms in 22q11DS.

  • Eli Lilly Acquires AtaiBeckley for $2.8 Billion Plus Contingent Value Rights
    July 17, 2026
    Buyer
    Eli Lilly and Company, Apeiron Investment Group, Ltd
    Target
    AtaiBeckley Inc.
    Industry
    Biotechnology
    Location
    New York, United States
    Type
    Buyout

    Eli Lilly and Company has entered into a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Under the terms, Lilly will pay $6.75 per share in cash plus up to $2.50 per share in contingent value rights tied to development and regulatory milestones for BPL-003 and VLS-01, with the deal expected to close in the third quarter subject to customary approvals. A later update indicates Lilly has completed the acquisition following AtaiBeckley shareholder approval, integrating the clinical-stage pipeline into Lilly’s neuroscience R&D organization.

  • NextCure and Avere Therapeutics Announce Merger and $320 Million Financing to Create Oral IL-23 Biotech
    July 17, 2026
    Buyer
    NextCure, Avere Therapeutics
    Target
    Avere Therapeutics, NextCure
    Industry
    Biotechnology
    Type
    Buyout

    NextCure and Avere Therapeutics have entered into a definitive all-stock merger that will create a publicly traded biotechnology company focused on developing once-weekly oral therapies for inflammatory diseases driven by interleukin-23. The transaction is supported by a concurrent $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group to fund key clinical milestones through Phase 2b and into Phase 3 development.

  • Jasper Therapeutics Acquires Kira Pharmaceuticals in All-Stock Merger
    July 16, 2026
    Buyer
    Jasper Therapeutics, Inc.
    Target
    Kira Pharmaceuticals
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Jasper Therapeutics has completed the acquisition of Kira Pharmaceuticals in an all-stock transaction, forming a combined company focused on advancing a consolidated immunology pipeline. Concurrent with the deal, Jasper arranged a $132 million private placement and Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upon signing, with potential development and sales milestones.

  • Glucotrack Acquires Lōkahi Therapeutics in Strategic Business Combination
    July 14, 2026
    Buyer
    Glucotrack, Inc.
    Target
    Lōkahi Therapeutics, Glucotrack, Inc.
    Industry
    Biotechnology
    Location
    New Jersey, United States
    Type
    Buyout

    Glucotrack, Inc. completed its strategic business combination with Lōkahi Therapeutics to establish a publicly listed, capital-efficient healthcare assets platform. The structure makes Lōkahi Therapeutics the operating and controlling business of the combined company, with Lōkahi Therapeutics securityholders receiving Glucotrack stock; they are expected to hold about 90% on a fully diluted basis.

  • Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care
    July 9, 2026
    Buyer
    Tarsus Pharmaceuticals
    Target
    iRenix Medical
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.

  • Novartis Acquires Myricx Bio (ADC NMTi Payload Platform) for Up to $1.5 Billion
    July 7, 2026
    Buyer
    Novartis
    Target
    Myricx Bio
    Seller
    Sofinnova Partners
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    Sofinnova Partners’ portfolio company Myricx Bio has agreed to be acquired by Novartis in a deal valued at up to $1.5 billion, including $1.1 billion in cash upfront plus potential milestone payments. Myricx Bio is a UK-headquartered biotech developing NMTi payloads and lead ADC assets targeting B7-H3 and HER2 for solid tumors.

  • United Therapeutics Acquires Thymmune Therapeutics
    July 3, 2026
    Buyer
    United Therapeutics
    Target
    Thymmune Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    United Therapeutics announced it has acquired Thymmune Therapeutics, a privately held preclinical-stage biotechnology company developing thymic regenerative cell therapies. The deal includes $140 million paid in cash upfront, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.

  • Hanmi Pharmaceutical Acquires Aptose Biosciences in Going-Private Transaction
    June 30, 2026
    Buyer
    Hanmi Pharmaceutical Co. Ltd., HS North America Ltd.
    Target
    Aptose Biosciences Inc.
    Industry
    Biotechnology
    Location
    Ontario, Canada
    Type
    Buyout

    Hanmi Pharmaceutical Co. Ltd., via wholly owned subsidiary HS North America Ltd., completed a plan of arrangement under which it acquired all outstanding shares of Aptose Biosciences that it did not already own. Aptose shareholders received C$2.41 in cash per common share, representing a 28% premium over the prior 30-day VWAP.

  • Ipsen Acquires Kartos Therapeutics for Up to $1.75 Billion
    June 29, 2026
    Buyer
    Ipsen
    Target
    Kartos Therapeutics
    Industry
    Biotechnology
    Location
    France
    Type
    Buyout

    Ipsen entered into a definitive merger agreement to acquire clinical-stage biopharmaceutical company Kartos Therapeutics. The deal brings navtemadlin, an oral MDM2 inhibitor in Phase III for TP53 wild-type myelofibrosis, into Ipsen’s late-stage oncology pipeline, with $450 million paid upfront and up to $1.3 billion in regulatory and sales-related milestones.

  • Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp
    June 29, 2026
    Buyer
    JATT II Acquisition Corp, Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, JATT Ventures II L.P.
    Target
    Talawar Therapeutics, Talawar Tx Inc
    Industry
    Biotechnology
    Location
    New Jersey, United States
    Type
    Buyout

    Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).

  • Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement
    June 25, 2026
    Buyer
    Serapha Bio, Boundless Bio
    Target
    Serapha Bio, Boundless Bio
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

  • AbbVie Acquires Apogee Therapeutics for $10.9 Billion
    June 22, 2026
    Buyer
    AbbVie
    Target
    Apogee Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    AbbVie entered into a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion ($135.11 per share). The deal is intended to deepen AbbVie’s immunology portfolio and expand its clinical presence in respiratory diseases, with Apogee’s lead program zurilokibart (APG777) targeting IL-13 for atopic dermatitis and its pipeline including APG273 for asthma. Closing was expected in Q3 2026, subject to customary regulatory and shareholder approvals; AbbVie later announced completion on Sept. 3, 2026.

  • 10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities
    June 10, 2026
    Buyer
    10x Genomics, Inc.
    Target
    Proteintech Genomics (a division within Proteintech Group)
    Seller
    Proteintech Group
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    10x Genomics announced it has acquired Proteintech Genomics, a division within Proteintech Group, to expand its proteomics capabilities for single-cell and spatial multiomics workflows on 10x platforms. The deal adds Proteintech Genomics’ Human Discovery Panel technology and supports 10x’s strategy of integrating transcriptomic and proteomic measurements, including capabilities planned for its Atera platform. Financial terms were not disclosed.

  • Copley Acquisition Corp and Aditxt Agree to Take Ignite Proteomics Public via Business Combination Valuing Company at ~$150 Million
    June 9, 2026
    Buyer
    Copley Acquisition Corp, Ignite Proteomics Holdings (newly formed public holding company)
    Target
    Ignite Proteomics, LLC
    Seller
    Aditxt, Inc.
    Industry
    Biotechnology
    Location
    Colorado, United States
    Type
    Buyout

    Copley Acquisition Corp and Ignite Proteomics (a wholly owned subsidiary of Aditxt) have entered into a definitive business combination agreement to take Ignite public. The transaction values Ignite at an implied equity value of approximately $150 million and is expected to create a newly formed holding company (Ignite Proteomics Holdings) with listings on the NYSE, with Ignite expected to become an independent public company following closing.

  • Incyte Acquires Vega Therapeutics to Expand Hematology Portfolio in Bleeding Disorders
    June 8, 2026
    Buyer
    Incyte
    Target
    Vega Therapeutics
    Seller
    Star Therapeutics, LLC
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront, with up to $750 million in additional milestone payments for total potential consideration of up to $2.0 billion. The deal is intended to add Vega’s Phase 3 monoclonal antibody candidate VGA039 for von Willebrand disease to Incyte’s hematology portfolio.

  • Johnson & Johnson to Acquire Firefly Bio for $1 Billion
    June 8, 2026
    Buyer
    Johnson & Johnson
    Target
    Firefly Bio, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. The deal is intended to expand Johnson & Johnson’s oncology pipeline using Firefly Bio’s proprietary Firelink degrader antibody conjugate platform, including preclinical candidates for KRAS-driven and other hard-to-treat solid tumors.

  • Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal
    June 2, 2026
    Buyer
    Rallybio Corporation
    Target
    Avenzo Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

  • Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion
    May 27, 2026
    Buyer
    Eli Lilly and Company
    Target
    Vaccine Company, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

  • Eli Lilly Acquires Engage Biologics
    May 23, 2026
    Buyer
    Eli Lilly and Company
    Target
    Engage Biologics Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.

  • InMed Pharmaceuticals to Merge with Mentari Therapeutics in $290M All-Stock Deal
    May 20, 2026
    Buyer
    InMed Pharmaceuticals, Inc., Fairmount, Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, Vivo Capital, Perceptive Advisors, Sirenia Capital Management LP, Oruka Therapeutics (Oruka Therapeutics executive board involvement)
    Target
    Mentari Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    InMed Pharmaceuticals (NASDAQ: INM) entered into a definitive all-stock merger agreement with privately held Mentari Therapeutics, creating a publicly traded migraine-focused biotech under the Mentari name. The transaction is supported by an oversubscribed $290 million private placement led by Fairmount to fund operations through 2028.

  • Quince Therapeutics Acquires Orphai Therapeutics in Stock-for-Stock Deal and Raises Up to $187M Private Placement
    May 19, 2026
    Buyer
    Quince Therapeutics, Inc.
    Target
    Orphai Therapeutics Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Quince Therapeutics, Inc. announced it has acquired Orphai Therapeutics Inc. in a stock-for-stock merger, bringing Orphai’s inhaled rapamycin (LAM-001) pulmonary pipeline into Quince. Concurrently, Quince entered into a definitive agreement for a private placement financing raising up to $187 million gross proceeds (including $115 million upfront), expected to fund clinical development milestones through 2028.

  • Zydus Worldwide DMCC to Acquire Assertio Holdings in All-Cash $166.4 Million Tender Offer
    May 13, 2026
    Buyer
    Zydus Worldwide DMCC, Zydus Lifesciences Limited, Zara Merger Sub Inc.
    Target
    Assertio Holdings, Inc.
    Industry
    Biotechnology
    Location
    Illinois, United States
    Type
    Buyout

    Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited, has entered into a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc. for $23.50 per share in cash, valuing the deal at approximately $166.4 million. The transaction is structured as a tender offer followed by a second-step merger at the same price and is expected to close in the second quarter of 2026 (2026–27 financial year in some reports), subject to customary conditions.

  • Blackstone Life Sciences Invests $250M in Anagram Therapeutics
    May 7, 2026
    Buyer
    Blackstone Life Sciences
    Target
    Anagram Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Growth capital

    Blackstone Life Sciences (BXLS) announced a $250 million investment in clinical-stage biotech Anagram Therapeutics to advance and commercialize its oral recombinant enzyme replacement therapy, ANG003, for exocrine pancreatic insufficiency (EPI) related to cystic fibrosis and other disorders. The funding is intended to support development through regulatory approval and market launch, including planned mid-stage clinical trials.

  • Bayer to Acquire Perfuse Therapeutics
    May 7, 2026
    Buyer
    Bayer
    Target
    Perfuse Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Bayer announced an agreement to acquire Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment plus development, regulatory, and commercial milestone payments. The deal is intended to strengthen Bayer’s ophthalmology pipeline by adding PER-001, an investigational therapy in Phase II for glaucoma and diabetic retinopathy.

  • UCB Acquires Candid Therapeutics
    May 3, 2026
    Buyer
    UCB
    Target
    Candid Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    UCB has agreed to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engagers for autoimmune and inflammatory diseases, for up to $2.2 billion including $2.0 billion upfront. Two River and Vida Ventures, part of the Bellco Health ecosystem, highlighted their roles in founding and early development of Candid following the announced acquisition.

  • UCB To Acquire Candid Therapeutics for Up to $2.2 Billion
    May 3, 2026
    Buyer
    UCB
    Target
    Candid Therapeutics
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal includes $2.0 billion in upfront payments and up to $200 million in potential milestone payments, and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance and customary conditions.

  • XTL Biopharmaceuticals to Acquire Psyga Bio to Build Psychedelic Biotechnology Platform
    April 30, 2026
    Buyer
    XTL Biopharmaceuticals
    Target
    Psyga Bio
    Industry
    Biotechnology
    Location
    Israel
    Type
    Buyout

    XTL Biopharmaceuticals has entered into a definitive share purchase agreement to acquire 100% of Psyga Bio. The deal is structured as a share exchange with no cash consideration at closing, with XTL issuing ADSs representing 40% of Psyga Bio’s issued and outstanding share capital plus milestone-based ADSs up to an additional 10%.

  • Chiesi Group acquires KalVista Pharmaceuticals
    April 29, 2026
    Buyer
    Chiesi Farmaceutici S.p.A., Chiesi Group
    Target
    KalVista Pharmaceuticals, Inc.
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Chiesi Farmaceutici S.p.A./Chiesi Group entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. for approximately $1.5 billion (about $1.9 billion at closing), paying $27.00 per share in cash via a tender offer and subsequent merger. The acquisition was completed on June 11, 2026, with KalVista becoming a wholly owned subsidiary and its stock ceasing to trade on Nasdaq.

  • Profluent and Eli Lilly Partner on AI-Designed Gene Editing Platform Deal (Up to $2.25B+ in Milestones)
    April 28, 2026
    Buyer
    Eli Lilly
    Target
    Profluent
    Industry
    Biotechnology
    Type
    Growth capital

    Air Street Capital portfolio company Profluent announced a multi-program strategic partnership with Eli Lilly to develop AI-designed recombinases for genetic medicine. Profluent will receive an upfront payment, committed R&D funding, and is eligible for up to $2.25 billion in development and commercial milestones, plus tiered royalties on net sales.

Full Export

Purchase this data

Get the full acquisitions list for this page as CSV + XLSX.

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Apply as a Buyer

Frequently Asked Questions

What types of biotechnology acquisitions are represented here?

The page highlights acquisitions and mergers involving drug discovery/preclinical tools, clinical-stage or program-focused companies, and broader platform combinations spanning ingredients, formulation, manufacturing, and commercialization capabilities.

Which buyers appear repeatedly in these biotechnology deals?

Recurring buyer names include Gilead Sciences, Inc., Avista Capital Partners, Ampersand Capital Partners, Lonza AG, Windjammer Capital Investors, and Ensign-Bickford Industries, Inc., along with Kite (a Gilead Company).

Which geographies show up in the most recent biotechnology transactions?

Recent deal locations referenced here include the United States, the United Kingdom, France, Lower Saxony, Germany, California and Florida in the U.S., and Iceland.

Do these deals usually include financing alongside the acquisition?

Several recent transactions are paired with private placements or structured financing plans—for example, deals featuring oversubscribed private placements or financing intended to fund development of acquired programs.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions in Canada Private Equity-Backed Biotechnology Buyers Biotechnology Acquisitions in 2026 Biotechnology Acquisitions in Ohio Biotechnology Acquisitions in Massachusetts Biotechnology Acquisitions in California Biotechnology Acquisitions in Florida Biotechnology Acquisitions in New York Biotechnology Acquisitions in New Jersey

Related articles